|
KMID : 1160420230050020060
|
|
Epilia: Epilepsy Commun
2023 Volume.5 No. 2 p.60 ~ p.64
|
|
|
A New Antiseizure Medication: Cenobamate
|
|
Shin Yong-Won
|
|
|
Abstract
|
|
|
|
Cenobamate is a novel antiseizure medication approved by the U.S. Food and Drug Administration and the European Medicines Agency, offering a new therapeutic option for drug-resistant focal onset seizures. Cenobamate exhibits dual-mode activity, inhibiting persistent sodium currents and enhancing inhibitory GABAergic synaptic transmission through allosteric modulation, thereby contributing to its antiepileptic effects. Several randomized clinical trials demonstrated significant reductions in seizure frequency and increased response rates with fair safety profiles. Long-term extension studies additionally confirmed sustained effectiveness and safety. In terms of potential side effects, studies have indicated the need for careful dosing during the initial titration phase due to the risk of hypersensitivity reactions. This review covers the mechanism of action, pharmacokinetic properties, drug interactions, efficacy, and safety of cenobamate.
|
|
|
KEYWORD
|
|
|
Cenobamate, Mechanisms of action, Pharmacokinetics, Drug interactions, Efficacy, Safety
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|